Cargando…
Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies
OBJECTIVE: This post hoc, pooled, subgroup analysis of two randomised studies evaluated baseline characteristics that may influence the efficacy and safety of naldemedine in patients with opioid-induced constipation (OIC) and cancer. METHODS: Data for patients who received 0.2 mg naldemedine or plac...
Autores principales: | Osaka, Iwao, Ishiki, Hiroto, Yokota, Takaaki, Tada, Yukio, Sato, Hiroki, Okamoto, Masaharu, Satomi, Eriko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677965/ https://www.ncbi.nlm.nih.gov/pubmed/31423335 http://dx.doi.org/10.1136/esmoopen-2019-000527 |
Ejemplares similares
-
Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
por: Saito, Yoji, et al.
Publicado: (2018) -
Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis
por: Kanbayashi, Yuko, et al.
Publicado: (2022) -
Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial
por: Ozaki, Anna, et al.
Publicado: (2022) -
Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer
por: Katakami, N, et al.
Publicado: (2018) -
A retrospective study of the efficacy and safety of naldemedine for opioid‐induced constipation in thoracic cancer patients
por: Imai, Hisao, et al.
Publicado: (2022)